Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 879 | 0.380 |
Why?
|
| Fatigue | 1 | 2017 | 1557 | 0.350 |
Why?
|
| Ambulatory Care | 1 | 2013 | 2783 | 0.200 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2017 | 3187 | 0.200 |
Why?
|
| Kidney Neoplasms | 1 | 2017 | 4282 | 0.180 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2018 | 11878 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2016 | 10399 | 0.160 |
Why?
|
| Pain | 1 | 2013 | 5100 | 0.150 |
Why?
|
| Disease-Free Survival | 6 | 2017 | 6847 | 0.140 |
Why?
|
| Antineoplastic Agents | 2 | 2017 | 13676 | 0.140 |
Why?
|
| Melanoma | 4 | 2017 | 5706 | 0.130 |
Why?
|
| Neoplasms | 2 | 2016 | 22371 | 0.130 |
Why?
|
| Vaccines, Subunit | 1 | 2015 | 159 | 0.120 |
Why?
|
| HLA-A2 Antigen | 1 | 2015 | 207 | 0.120 |
Why?
|
| Paclitaxel | 3 | 2015 | 1733 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2017 | 336 | 0.100 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2015 | 892 | 0.100 |
Why?
|
| Taxoids | 1 | 2015 | 667 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2015 | 696 | 0.100 |
Why?
|
| GTP Phosphohydrolases | 1 | 2014 | 525 | 0.090 |
Why?
|
| Ovary | 1 | 2014 | 965 | 0.090 |
Why?
|
| Tamoxifen | 1 | 2014 | 966 | 0.090 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2017 | 3556 | 0.080 |
Why?
|
| Tumor Burden | 1 | 2015 | 1906 | 0.080 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 20227 | 0.080 |
Why?
|
| Breast Neoplasms | 4 | 2018 | 21206 | 0.070 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 1375 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 10101 | 0.060 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2014 | 2059 | 0.060 |
Why?
|
| Adaptation, Psychological | 1 | 2015 | 2663 | 0.060 |
Why?
|
| Pain Measurement | 1 | 2013 | 3583 | 0.050 |
Why?
|
| Peptide Fragments | 1 | 2015 | 5151 | 0.050 |
Why?
|
| Survival Rate | 4 | 2018 | 12840 | 0.050 |
Why?
|
| Niacinamide | 2 | 2014 | 418 | 0.050 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2017 | 4058 | 0.050 |
Why?
|
| Middle Aged | 10 | 2018 | 223492 | 0.050 |
Why?
|
| Double-Blind Method | 4 | 2018 | 12465 | 0.050 |
Why?
|
| Neoplasm Staging | 4 | 2017 | 11244 | 0.040 |
Why?
|
| Carboplatin | 2 | 2014 | 797 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 12077 | 0.040 |
Why?
|
| Phenylurea Compounds | 2 | 2014 | 531 | 0.040 |
Why?
|
| Aged | 7 | 2018 | 171504 | 0.040 |
Why?
|
| Anxiety | 1 | 2015 | 4672 | 0.040 |
Why?
|
| Adult | 8 | 2017 | 223646 | 0.040 |
Why?
|
| Logistic Models | 1 | 2013 | 13290 | 0.040 |
Why?
|
| Receptors, Estrogen | 2 | 2018 | 2253 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2014 | 7876 | 0.030 |
Why?
|
| Drug Administration Schedule | 2 | 2015 | 4860 | 0.030 |
Why?
|
| Immunocompetence | 1 | 2017 | 138 | 0.030 |
Why?
|
| Female | 10 | 2018 | 397192 | 0.030 |
Why?
|
| Treatment Outcome | 3 | 2018 | 65371 | 0.030 |
Why?
|
| Quality of Life | 2 | 2015 | 13490 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2013 | 15948 | 0.030 |
Why?
|
| Humans | 12 | 2018 | 768166 | 0.030 |
Why?
|
| Male | 7 | 2017 | 364719 | 0.030 |
Why?
|
| Aromatase Inhibitors | 1 | 2018 | 519 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2018 | 1760 | 0.030 |
Why?
|
| Colorectal Neoplasms | 1 | 2013 | 6974 | 0.030 |
Why?
|
| Protein Isoforms | 1 | 2017 | 1715 | 0.020 |
Why?
|
| Time Factors | 1 | 2013 | 40218 | 0.020 |
Why?
|
| Fluorouracil | 1 | 2017 | 1652 | 0.020 |
Why?
|
| Prostatic Neoplasms | 1 | 2013 | 11101 | 0.020 |
Why?
|
| Cisplatin | 1 | 2017 | 1660 | 0.020 |
Why?
|
| Premenopause | 1 | 2014 | 1039 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2014 | 1160 | 0.020 |
Why?
|
| Cyclophosphamide | 1 | 2015 | 2227 | 0.020 |
Why?
|
| Mutation | 1 | 2014 | 30238 | 0.020 |
Why?
|
| Follow-Up Studies | 3 | 2015 | 39348 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2013 | 13586 | 0.020 |
Why?
|
| Postmenopause | 1 | 2018 | 2518 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2015 | 2234 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2018 | 2603 | 0.020 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 59629 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 2914 | 0.020 |
Why?
|
| Risk Factors | 1 | 2013 | 74944 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2014 | 1536 | 0.020 |
Why?
|
| Skin Neoplasms | 2 | 2015 | 5863 | 0.020 |
Why?
|
| Population Surveillance | 1 | 2015 | 2596 | 0.010 |
Why?
|
| Prognosis | 2 | 2015 | 30010 | 0.010 |
Why?
|
| Vaccination | 1 | 2015 | 3437 | 0.010 |
Why?
|
| Lymph Nodes | 1 | 2014 | 3474 | 0.010 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2012 | 6526 | 0.010 |
Why?
|
| Cytokines | 1 | 2017 | 7453 | 0.010 |
Why?
|
| Health Status | 1 | 2015 | 4091 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2017 | 17140 | 0.010 |
Why?
|
| Genotype | 1 | 2014 | 13045 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 2015 | 4530 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2015 | 14783 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 13671 | 0.010 |
Why?
|
| Depression | 1 | 2015 | 8230 | 0.010 |
Why?
|
| Obesity | 1 | 2015 | 13090 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2015 | 41754 | 0.010 |
Why?
|
| Young Adult | 1 | 2015 | 60066 | 0.000 |
Why?
|
Concepts
(93)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(7)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_